■心房颤动(AF)伴有不同程度的炎症和纤维化。在具有不同形式的AF和心脏状态的患者中测量纤维化的生物标志物。在这里,在心脏结构正常的患者中,我们评估了不同生物标志物的基线浓度与肺静脉隔离术(PVI)长期成功的相关性.此外,我们比较了消融前和消融后3年的生物标志物水平,以进一步了解房颤机制.
■患者,前瞻性纳入因阵发性/持续性房颤而接受PVI治疗的患者.在消融前24小时和消融后3年获得血样。血清癌症抗原125(CA-125),测定血浆胱天蛋白酶-3、半乳糖凝集素-3和组织蛋白酶L的浓度。每6个月的随访包括12导联心电图,24小时Holter,消融后的电话监测以及经胸超声心动图。生物标志物水平,在基线和3年随访时,我们比较了有和无房颤复发患者的左心室射血分数和左心房(LA)直径.
■共纳入63名患者(23名女性;年龄61.4(±8.8)岁)。所有患者均实现了所有肺静脉的急性隔离。在平均36.3±6.3个月的随访中,26例(41.3%)患者出现房颤复发。与无房颤复发患者相比,消融前后CA-125、Galectin-3、Caspase-3和组织蛋白酶L水平无显著差异。在随访期间检测到Caspase-3、Galectin-3和CathepsinL的浓度显著下降,房颤复发患者与无房颤复发患者无差异。在房颤复发组术前(r=0.477;p=0.018)和术后(r=0.533;p=0.019),Caspase-3水平与LA直径呈正相关。
■我们的结果表明CA-125、Caspase-3、CathepsinL和Galectin-3的水平与心脏结构正常且主要为阵发性房颤的患者PVI后房颤复发无关。除CA-125外,所有其他生物标志物均在消融后3年随访期间显着下降。此外,在房颤复发患者中,Caspase-3水平与LA大小呈正相关。
UNASSIGNED: Atrial fibrillation (AF) is accompanied by inflammation and fibrosis to variable extent. The biomarkers of fibrosis were measured in patients with different forms of AF and cardiac status. Herein, we assessed the associations of the baseline concentrations of different biomarkers with the long-term success of pulmonary vein isolation (PVI) in patients with a structurally normal heart. Furthermore, we compared biomarker levels before and 3 years after ablation to gain further insights into the AF mechanism.
UNASSIGNED: Patients, undergoing PVI for paroxysmal/persistent AF were enrolled prospectively. Blood samples were obtained 24 hours before and 3 years after ablation. Serum cancer antigen 125 (CA-125), plasma Caspase-3, Galectin-3 and Cathepsin L concentrations were measured. Follow-up visits every 6 months included 12-lead electrocardiogram, 24-hour Holter, trans-telephonic monitoring as well as transthoracic echocardiography after ablation. Biomarker levels, left ventricular ejection fraction and left atrial (LA) diameters at baseline and at the 3-year follow-up were compared in patients with versus without AF recurrence.
UNASSIGNED: A total of 63 patients were enrolled (23 women; age 61.4 ( ± 8.8) years). The acute isolation of all pulmonary veins was achieved in all patients. During a mean follow-up of 36.3 ± 6.3 months, AF recurrence was demonstrated in 26 (41.3%) patients. No significant differences were demonstrated in the levels of CA-125, Galectin-3, Caspase-3 and Cathepsin L pre- and post-ablation in patients with versus without AF recurrence. A significant decrease was detected in the concentrations of Caspase-3, Galectin-3 and Cathepsin L during follow-up with no difference in patients with versus without AF recurrence. A positive correlation was found between Caspase-3 levels and LA diameters in the AF recurrence group both before (r = 0.477; p = 0.018) and after the procedure (r = 0.533; p = 0.019).
UNASSIGNED: Our results demonstrated that the levels of CA-125, Caspase-3, Cathepsin L and Galectin-3 are not associated with AF recurrence after PVI in patients with a structurally normal heart and mainly paroxysmal AF. Except for CA-125, all the other biomarkers demonstrated a significant decrease during a 3-year follow-up post-ablation. Furthermore, Caspase-3 levels demonstrated a positive correlation with LA dimensions in patients with AF recurrence.